Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Fera Pharmaceuticals has acquired Itraconazole, an investigational new drug to treat fungal otitis externa (FOE).
Subscribe to our email newsletter
In a Phase2 pilot study, Itraconazole topical suspension was shown to be effective in the treatment of FOE with no adverse events reported.
Fera Pharma is working to complete Phase 3 clinical development required to obtain FDA approval. Itraconazole has already got orphan drug designation from the FDA.
Frank DellaFera, president of Fera Pharma, said: “This acquisition fulfills a strategic imperative for Fera, product development and commercialisation in specialty and underserved therapeutic categories.”
It is said that the mechanism of action of Itraconazole is the same as the other azole antifungals, it inhibits the fungal cytochrome P450 oxidase-mediated synthesis of ergosterol.
Itraconazole capsules are used to treat fungal infections that begin in the lungs and can spread through the body. Itraconazole capsules are also used to treat fungal infections of the fingernails and/or toenails, yeast infections of the mouth and throat and suspected fungal infections in patients with fever and certain other signs of infection.